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Abstract. Essential oils from various aromatic plants have
been reported to exert chemopreventive and/or antitumor
effects. In addition, a number of studies have shown the
ability of chemopreventive phytochemicals to increase the
sensitivity of cancer cells to conventional anticancer drugs.
The success of chemotherapeutic agents is often hindered by
the development of drug resistance, with multidrug resistant
(MDR) phenotypes reported in a number of tumors, generally
involving reduced intracellular drug accumulation due to
increased drug efflux by membrane transporters. In the present
study, the effects of linalool (LIN), a monoterpene alcohol
found in the essential oils from many aromatic plants, on the
growth of two human breast adenocarcinoma cell lines, MCF7
WT and multidrug resistant MCF7 AdrR, were investigated,
both as a single agent and in combination with doxorubicin
(DOX). The results reported here show that LIN only
moderately inhibits cell proliferation; interestingly, however,
subtoxic concentrations of LIN potentiate DOX-induced
cytotoxicity and pro-apoptotic effects in both cell lines. A
significant synergism can be observed in MCF7 AdrR cells,
which may be due, at least in part, to the ability of LIN to
increase DOX accumulation and to induce a decrease in Bcl-xL
levels. In summary, the results of the present study suggest
that LIN may improve the therapeutic index of anthracyclines
in the management of breast cancer, especially in MDR
tumors.
Introduction
The pharmaceutical properties of aromatic plants are partially
attributed to their volatile extracts (essential oils), containing
a wide variety of active phytochemicals, such as flavonoids,
monoterpenes, and polyphenols, among many others (1). In
recent years, essential oils from many different herbs and
phytochemicals derived thereof have been reported to exert
chemopreventive and/or antitumor effects through a number
of mechanisms (2-4). These observations have suggested a
potential use for these compounds as an alternative to
chemically designed antineoplastic agents, or as adjuvant
treatments (5); however, increasing evidence from in vitro
and animal models indicates that combining dietary-derived
phytochemicals with conventional antineoplastic drugs is
probably the most promising application for these compounds
(6). The success of both cytotoxic and targeted chemo-
therapeutic agents is often hindered by the development of
drug resistance, and particularly multidrug resistance (MDR),
a condition most commonly involving altered expression/
function of energy-dependent drug transporters belonging to
the ABC (ATP-binding cassette) superfamily, leading to
reduced intracellular drug accumulation, and/or impairment
of one or more steps of the apoptotic signalling cascades (7).
Several phytochemicals, including curcumin, indole-3-
carbinole (I3C), epigallocatechin gallate and resveratrol have
been shown to reverse MDR mediated by ABC transporters
(8-10).
The present study focuses on the antiproliferative and
chemosensitizing properties of linalool (Fig. 1), an acyclic
monoterpene alcohol found in the essential oils from many
aromatic plants, including lavender (Lavandula officinalis),
coriander seeds (Coriandrum sativum) and sweet basil
(Ocimum basilicum). Linalool is the main constituent of
the volatile extract of Mentha citrata (11), also known as
Bergamot mint, original of central and southern Europe and
still widely cultivated for its antiseptic and digestive properties.
Linalool is used as an additive for processed food and
beverages and even more commonly as a fragrance ingredient
in cosmetics, toiletries and household detergents (12). Studies
on linalool-containing essential oils indicate that this compound
possesses antimicrobic, antibacterial and antiviral effects
(13-17), as well as anti-inflammatory, analgesic and local
anaesthetic activities (18-20). As several plant-derived mono-
terpenes have been shown to prevent and arrest tumor growth
(reviewed in refs. 21-23), recent studies have focused the
chemopreventive/chemotherapeutic potential of linalool, with
contrasting results (24-26).
In the present study the effects of linalool (LIN) on the
growth of two human breast adenocarcinoma cell lines,
MCF7 WT and MCF7 AdrR were investigated; the latter was
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derived from MCF7 WT cells by continuous exposure to
doxorubicin (DOX) and exhibits a typical MDR phenotype,
characterized by P-glycoprotein (Pgp or ABCB1, according
to the current classification) overexpression and by reduced
intracellular drug accumulation (27,28). In addition, the ability
of LIN to modulate DOX cytotoxicity in both cell lines was
also assessed. The results reported here show that LIN as a
single agent has weak antiproliferative effects on MCF WT
and AdrR cells; however, when subtoxic concentrations of
LIN are combined with DOX, the cytotoxic and pro-apoptotic
effects of the anthracycline are potentiated in both cell lines.
A significant synergy is observed in MCF7 AdrR cells exposed
to the LIN/DOX combination, which seems to be due, at least
in part, to the ability of LIN to increase DOX accumulation,
possibly by interfering with Pgp-mediated drug efflux.
Determination of the intracellular levels of proteins involved
in cell cycle control and/or apoptosis, including p53, p21waf1/cip1,
Bcl2, Bax, Bcl-xL and survivin, only indicates a possible
involvement of Bcl-xL, which is decreased in MCF7 AdrR
cells following LIN treatment.
Materials and methods
Chemicals and reagents. Linalool (LIN) was purchased
from Tebu-Bio S.r.l. (Magenta, Italy). 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), and
standard reagents were purchased from Sigma-Aldrich S.r.l.
(Milan, Italy). Doxorubicin (DOX) was kindly provided by
Dr A. Suarato (Nerviano Medical Sciences, Nerviano, Italy)
and dissolved in water as a 10 mM stock solution.
Cells and in vitro culture conditions. MCF7 WT cells, obtained
from ATCC (Manassas, VA) and MCF7 AdrR cells, the MDR
variant of MCF7 WT selected for resistance to DOX and
kindly provided by Dr K. Cowan (University of Nebraska
Medical Center), were cultured in DMEM medium, supple-
mented with 10% fetal bovine serum, 1% glutamine and 1%
antibiotics mixture at 37˚C under 5% CO2.
Cytotoxicity studies. The antiproliferative effects of DOX,
LIN and their combinations were assessed in human breast
adenocarcinoma MCF7 WT and MCF7 AdrR cells by the
MTT assay (29). Briefly, cells were seeded onto 96-well plates,
allowed to attach and grow for 24 h and subsequently exposed
to different DOX concentrations (0.05-10 μM for MCF7 WT
cells; 1-250 μM for MCF7 AdrR cells) in the presence or
absence of fixed subtoxic LIN concentrations (10 and 50 μM)
for 72 h. At the end of the treatment, MTT (2 mg/ml in PBS)
was added for 3 h at 37˚C; formazan crystals, formed by
mitochondrial reduction of MTT, were solubilized in DMSO
and the absorbance was read at 570 nm, using a Universal
Microplate reader EL800 (Bio-Tek Instruments, Winooski,
VT).
IC50 values were calculated by the median effect equation;
differences between IC50 values were analyzed statistically
by two-way analysis of variance with Bonferroni post-test for
multiple comparisons, using Prism 3.03 (GraphPad Software,
Inc.). The interaction between LIN and DOX was analyzed
using the CalcuSyn software (Biosoft Cambridge, MA),
based on the method described by Chou & Talalay (30).
According to this method, a combination index (CI) can be
calculated from dose-response curves obtained following
exposure to DOX and/or LIN as single agents and in
combination. CI values approximating 1.0 indicate additive
interactions between the two agents; CI<1.0 indicates synergy
and, conversely, CI>1.0 indicates antagonism.
Flow cytometric studies. The induction of apoptotic cell
death and the effect on cell cycle distribution by 24 h exposure
to LIN (50 μM) were evaluated by flow cytometry. Cells
exposed to LIN were detached by trypsinization, washed in
phosphate-buffered saline (PBS) and fixed in ice-cold 70%
ethanol for 20 min at -20˚C. After a further wash in PBS,
DNA was stained with 50 μg/ml propidium iodide in PBS in
the presence of RNAse A (30 U/ml) at 37˚C for 30 min.
Accumulation studies were also performed by flow
cytometry, following 24 h pretreatment of MCF7 WT and
MCF7 AdrR with 50 μM LIN; 10 μM DOX was added for
the last 2 h of incubation. At the end of the treatment period,
the cells were rapidly washed with ice-cold PBS, detached
with EDTA and trypsin, resuspended in ice-cold PBS and
analyzed.
All samples were analyzed with a FACScan flow cyto-
meter (Becton-Dickinson Mountain View, CA) equipped
with a 15 mW, 488 nm, and an air-cooled argon ion laser.
Fluorescent emissions were collected through a 575 nm
band-pass filter, both for DOX or PI, and acquired in log
mode. At least 10,000 events were analyzed for each sample.
The percentage of apoptotic cells in each sample was
determined based on the sub-G1 peaks detected in mono-
parametric histograms; for DOX accumulation studies,
fluorescence intensity was expressed as mean fluorescence
channel (MFC) calculated from the flow cytometric profiles
by the CellQuest software (Becton-Dickinson).
Immunodetection of p53, p21, Bcl2, Bax, Bcl-xL and survivin.
MCF7 WT and MCF7 AdrR cells were exposed to 50 μM
LIN for 24 h and protein extracts were obtained. In most
cases 30 μg of protein per lane were loaded onto polyacry-
lamide gels (11%) and separated under denaturing conditions;
only in the case of Bcl2 immunodetection 150 μg of protein
were loaded (instead of the usual 30). Protein bands were
then transferred onto Immobilon P membranes (Millipore,
Bedford, MA, USA), and Western blot analysis was per-
formed by standard techniques with the following antibodies:
mouse monoclonal anti-human Bcl2 (100) and anti-p53
(DO-1); rabbit polyclonal anti-human Bax (N-20), rabbit
monoclonal anti-human p21 (C-19) (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA, USA); mouse monoclonal anti-
Bcl-xL (MBL Co., Japan); rabbit polyclonal anti-survivin
(Abcam, Cambridge, UK). Protein bands were visualized
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Figure 1. Molecular structure of Linalool.
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using a peroxidase-conjugated anti-mouse/rabbit secondary
antibody and the Supersignal West Pico Chemiluminescence
Substrate (Pierce, Milan).
Results
Cytotoxicity studies. As a single agent, LIN only exerts weak
antiproliferative effects against MCF7 WT and MCF7 AdrR
cells, yielding IC50 values of 200.48±48.31 μM and
128.26±19.95 μM (mean ± SE of 4 independent experiments),
respectively; the outcome is not significantly affected by the
presence of a typical MDR phenotype. Table I reports the
IC50 values extrapolated from the dose-response curves
obtained in MCF7 WT and MCF7 AdrR cells following 72 h
treatment with increasing concentrations of DOX in the
presence or absence of two subtoxic concentrations of LIN
(10 and 50 μM). As expected, MCF7 AdrR cells were more
resistant to DOX than MCF7 WT cells. The results obtained
with the LIN/DOX combinations indicate that LIN increases
the cytotoxicity of DOX in a dose-dependent fashion in both
cell lines; CI values (also reported in Table I) indicate a
significant synergistic effect between DOX and LIN in MCF7
AdrR for both LIN concentrations, whereas in MCF7 WT
cells an additive interaction was observed between the two
compounds.
Apoptosis detection. Fig. 2 shows the percentage of apoptotic
cells obtained by flow cytometric analysis of MCF7 WT and
MCF7 AdrR cells following 24 h exposure to DOX (0.5 μM)
and LIN (50 μM) as single agents or in combination. Again
as expected, the parental cell line was more sensitive to the
pro-apoptotic effect of DOX than the multidrug resistant
variant. No significant increase in apoptosis induction over
control values was observed in either cell lines when LIN was
used as a single agent. When DOX and LIN were combined, a
significant increase in the percentage of apoptotic cells was
observed in both cell lines as compared both to control values
and to the values obtained with the two compounds as single
agents.
Cell cycle analysis. The effects of LIN (50 μM for 24 h),
both as a single agent and in combination with DOX (0.5 μM),
on cell cycle distribution of MCF7 WT and MCF7 AdrR cells
are reported in Fig. 5. In both cell lines 24 h exposure to LIN
or DOX as single agents induces an increase in the G2/M and
a decrease in the G1 phase cell subpopulations. In MCF7 WT
cells, simultaneous exposure to DOX and LIN results in a
decrease in the percentage of cells in the G1 phase, while in
MCF7 AdrR cell line a relevant increase in the G2/M cell
subpopulation and a parallel decrease in G1 cells can be
observed.
Effect of LIN on DOX accumulation. Fig. 3 shows the results
obtained by flow cytometric analysis of intracellular DOX
levels in MCF7 WT and MCF7 AdrR cells following exposure
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Table I. Cytotoxic effects of DOX (72 h), as a single agent or in combination with subtoxic concentrations of LIN, on MCF7
WT and MCF7 AdrR cells (mean ± SE of 4 independent experiments). CI, combination index (see text).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
DOX DOX + LIN 10 μM DOX + LIN 50 μM
–––––––––– –––––––––––––––––––––––– ––––––––––––––––––––––––––
IC50 (μM) IC50 (μM) CI IC50 (μM) CI
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
MCF7 WT 1.16±0.18 0.79±0.09 0.9-1.1 0.62±0.09 0.8-1.1
MCF7 AdrR 16.16±0.94a 3.0±0.25b 0.5-0.8 1.24±0.26b 0.3-0.5
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
ap<0.05 vs MCF7 WT; bp<0.05 vs DOX.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Figure 2. Induction of apoptosis in MCF7 WT and MCF7 AdrR cells
following 24 h exposure to DOX (0.5 μM) and/or LIN (50 μM). Mean ±
SEM of three independent experiments. *p<0.05 vs. control; †p<0.001 vs.
control; ‡p<0.001 vs. control and vs. DOX.
Figure 3. Intracellular accumulation of DOX (10 μM for 2 h) in MCF7 WT
and MCF7 AdrR cells following 24 h exposure to LIN (50 μM). Mean ±
SEM of three independent experiments. *p<0.001 vs. control; **p<0.001 vs.
control and DOX alone.
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to 10 μM DOX for 2 h. Pretreatment with a subtoxic concen-
tration of LIN (50 μM) for 24 h (including simultaneous
exposure to the two agents for the last 2 h) induces a signi-
ficant increase in DOX accumulation in MCF7 AdrR cells as
compared to cells exposed to the anthracycline alone. In
contrast, the amount of DOX detected in MCF7 WT cells is
not significantly affected by LIN treatment.
Expression of p53, p21, Bcl2, Bax, Bcl-xL and survivin. Fig. 4
shows the effect of 50 μM LIN for 24 h on the intracellular
levels of p53, Bax, Bcl2, Bcl-xL, survivin and p21 in MCF7
WT and MCF7 AdrR cells. As expected, MCF7 AdrR cells,
that harbor a mutant form of the gene, exhibit higher p53
levels than MCF7 WT cells, with a wild-type p53 gene. LIN
treatment induces a modest increase of p53 levels in MCF7
AdrR cells, while protein expression is unaffected in MCF7
WT cells. p21 levels can only be detected in MCF7 WT
and are unmodified following LIN exposure. Both cell lines
express similar levels of Bax and survivin, which are not
affected by treatment with LIN. Bcl2 levels are significantly
higher in the parental than in the resistant cell line, but are
not affected by LIN treatment. In contrast, Bcl-xL is present
at higher levels in MCF7 AdrR than in MCF7 WT cells;
interestingly, 24 h exposure to LIN induces a decrease in
Bcl-xL in the resistant cell line, whereas in the parental cell
line a slight increase can be observed.
Discussion
Monoterpenes are non-nutritive dietary components found in
the essential oils of citrus fruits, mint and herbs and they are
largely responsible for the distinctive fragrance of these plants.
A number of dietary monoterpenes, such as d-limonene,
carvone and perillyl alcohol, have shown antitumor activity
in different experimental models, including breast cancer,
exhibiting not only the ability to prevent the formation or
progression of cancer, but to induce the regression of existing
malignant tumors, likely by more than one molecular
mechanism (21-23,31-33). Accordingly, both limonene and
perillyl alcohol have progressed into clinical trials. However,
results from phase II trials with these compounds in patients
with advanced solid tumors have been disappointing so far
(34,36,37).
A number of reports indicating the ability of herbs and
their components to interfere with drug transporters (38)
suggest a different application for monoterpenes in the
management of neoplastic disease, i.e. a possible use as chemo-
sensitizers; however, this issue has not received much attention
to date (14).
In the present study, we show that the monoterpene
alcohol LIN has indeed the ability to sensitize human breast
cancer cells, and particularly those exhibiting a Pgp-mediated
resistant phenotype, to the cytotoxic activity of DOX. Currently
available data on the chemopreventive and chemotherapeutic
potential of LIN are somewhat controversial (24-26). The
results obtained in our studies using LIN as a single agent
are in agreement with the observation reported by Kubo and
Morimitsu (23), indicating that LIN has a very weak
antiproliferative effect on breast cancer cells. Interestingly,
however, when subtoxic concentrations of LIN are
combined with DOX, the cytotoxic activity of the anthra-
cycline is synergistically increased in the multidrug resistant
cell line; in the parental cell line a dose-dependent decrease
in the IC50 of DOX can be observed with increasing LIN
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Figure 4. Effect of 24 h exposure to LIN (50 μM) on p53, p21, Bax, Bcl2,
Bcl-xL and survivin protein levels in MCF7 WT and MCF7 AdrR cells.
Figure 5. Effect of 24 h exposure to LIN (50 μM) and DOX (0.5 μM), as
single agents or in combination, on the cell cycle distribution of MCF7 WT
and MCF7 AdrR cells.
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concentrations, but this effect does not attain statistical
significance, and the calculated CI values indicate that the
interaction between the two compounds is additive at best.
These results are supported by data on apoptosis induction by
DOX in the two cell lines: again, simultaneous exposure to
LIN (50 μM), which per se does not increase the percentage
of apoptotic cells above control values, significantly
potentiates the effect of 0.5 μM DOX in 24 h; however, in
this case a significant increase is observed in MCF7 WT as
well as in MCF7 AdrR cells. The increase in G2/M phase,
observed when cells were simultaneously exposed to LIN
and DOX, indicates a premature entry into M-phase and
might explain the decrease in cell viability and the increase in
apoptosis induction observed in both cell lines.
The relevance of these observations should be discussed
in the context of the potential clinical application of LIN as a
chemosensitizing agent. As a result of its wide use as a food
additive and as a fragrance ingredient in cosmetics and
detergents, a wealth of toxicological data are available on
this compound (12) indicating that exposure by different
routes is substantially safe. In contrast, pharmacokinetic data
are scarce, and only concern transdermal and inhalation-
dependent routes, whereas, to our knowledge, no studies have
been published following oral or intraperitoneal administration
(35). However, the available data concur to suggest that
chemosensitizing LIN levels can be achieved in plasma
following dermal application or inhalation without undue
systemic toxicity.
To explain the synergy between LIN and DOX in MCF7
cells, we first assessed the effect of LIN on intracellular
DOX accumulation. This approach was suggested by the
observation that MCF7 AdrR cells, which are known to
accumulate lower drug amounts due to overexpression of the
Pgp efflux pump, are also more susceptible to the chemo-
sensitizing effect of LIN. Flow cytometric data showed
significantly lower levels of DOX in MCF7 AdrR than in
MCF7 WT cells, as expected, and pretreatment with LIN was
able to restore DOX accumulation in the resistant cells, while
drug levels were unaffected in the parental cell line. These
data suggest the hypothesis that LIN interferes with DOX
transport mechanisms that are overexpressed in the resistant
cell line and Pgp is a logical candidate target for LIN action,
even though this point was not specifically addressed in this
preliminary study. However, this is probably not the only
mechanism involved in the LIN/DOX interaction: in fact,
LIN was able to increase apoptosis induction by DOX not
only in the resistant, but in the parental cell line as well.
Therefore we also examined the effects of LIN on the intra-
cellular levels of a small panel of proteins controlling the cell
cycle and/or apoptotic pathways. Western blot analysis of
protein extracts from both cell lines did not show relevant
alterations in the protein levels of p53, p21waf1/cip1, Bax, Bcl2
and survivin following LIN exposure for 24 h. On the other
hand, the results obtained for Bcl-xL were somewhat
unexpected, with an evident down-regulation of this protein
by LIN in MCF7 AdrR cells, which could account for the pro-
apoptotic outcome observed in this cell line, but a slight up-
regulation of the same in MCF7 WT cells, which is in
contrast with the observed potentiation of DOX-induced
apoptosis.
To conclude, the studies presented here on the LIN/DOX
combination in breast cancer cells appear to support LIN as a
chemosensitizing agent, particularly in MDR cells; further
studies will be required to explore and explain the mechanistic
basis of this interaction.
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